Modified fibroblast growth factor 21 (FGF-21) for use in methods for treating… Grant US-11642395-B2 United States of America 09 May 2023
Methods of manufacture of immunocompatible chorionic membrane products Grant US-11638725-B2 United States of America 02 May 2023
Immunocompatible chorionic membrane products Grant US-11590172-B2 United States of America 28 Feb 2023
Methods of manufacture of therapeutic products comprising vitalized placental dispersions Grant US-11590173-B2 United States of America 28 Feb 2023
Methods of manufacture of immunocompatible amniotic membrane products Grant US-11510947-B2 United States of America 29 Nov 2022
Recombinant modified fibroblast growth factors and therapeutic uses thereof Grant US-11479591-B2 United States of America 25 Oct 2022
Methods of treating diseases associated with fibrosis using modified FGF-21 polypeptides Grant US-11248031-B2 United States of America 15 Feb 2022
Immunocompatible amniotic membrane products Grant US-11207353-B2 United States of America 28 Dec 2021
Modified FGF-21 polypeptides and their uses Grant US-10961291-B2 United States of America 30 Mar 2021
Methods of manufacture of therapeutic products comprising vitalized placental dispersions Grant US-10646519-B2 United States of America 12 May 2020
Methods of manufacture of immunocompatible amniotic membrane products Grant US-10576104-B2 United States of America 03 Mar 2020
Methods of treating diseases associated with fibrosis using modified FGF-21 polypeptides… Grant US-10377806-B2 United States of America 13 Aug 2019
Modified FGF-21 polypeptides comprising non-naturally encoding amino acids and their uses Grant US-10377805-B2 United States of America 13 Aug 2019
Immunocompatible amniotic membrane products Grant US-10272116-B2 United States of America 30 Apr 2019
Methods of manufacture of immunocompatible chorionic membrane products Grant US-10258650-B2 United States of America 16 Apr 2019
Therapeutic uses of modified FGF-21 polypeptides Grant US-10189883-B2 United States of America 29 Jan 2019
Nucleic acids encoding modified FGF-21 polypeptides comprising non-naturally occurring… Grant US-9975936-B2 United States of America 22 May 2018
Methods of manufacture of therapeutic products comprising vitalized placental dispersions Grant US-9956248-B2 United States of America 01 May 2018
Modified FGF-21 polypeptides comprising an internal deletion and uses thereof Grant US-9631004-B2 United States of America 25 Apr 2017
Methods of treatment using modified FGF-21 polypeptides comprising non-naturally… Grant US-9517273-B2 United States of America 13 Dec 2016
Modified FGF-21 polypeptides comprising an internal deletion and uses thereof Grant US-9434778-B2 United States of America 06 Sep 2016
Modified FGF-21 polypeptides comprising non-naturally occurring amino acids Grant US-9079971-B2 United States of America 14 Jul 2015
Modified Clostridial toxins with enhanced targeting capabilities for endogenous… Application US-8623999-B2 United States of America 07 Jan 2014
Methods of making FGF-21 mutants comprising non-naturally encoded phenylalanine… Grant US-8383365-B2 United States of America 26 Feb 2013
Modified clostridial toxins with enhanced translocation capability and enhanced targeting… Application EP-2505592-A1 European Patent Office 03 Oct 2012
INHIBITING ABERRANT BLOOD VESSEL FORMATION USING GROWTH FACTOR RETARGETED ENDOPEPTIDASES Application WO-2012112422-A1 World Intellectual Property Organisation (WIPO) 23 Aug 2012
Compounds capable of affecting differentiation, proliferation, regeneration, plasticity… Grant US-8071549-B2 United States of America 06 Dec 2011
Modified clostridial toxins with enhanced targeting capabilities for endogenous… Application EP-2316847-A2 European Patent Office 04 May 2011
METHODS OF TREATING CANCER USING GROWTH FACTOR RETARGETED ENDOPEPTIDASES Application WO-2011020115-A2 World Intellectual Property Organisation (WIPO) 17 Feb 2011
BOTULINUM TOXIN SCREENING ASSAYS Application WO-2010135538-A1 World Intellectual Property Organisation (WIPO) 25 Nov 2010